The Impact of Novel Immunosuppressive Agents on Infections in Organ Transplant Recipients and the Interactions of These Agents with Antimicrobials
Open Access
- 1 July 2002
- journal article
- Published by Oxford University Press (OUP) in Clinical Infectious Diseases
- Vol. 35 (1) , 53-61
- https://doi.org/10.1086/340867
Abstract
Several of the new immunosuppressive agents that are used to treat transplant recipients possess in vitro activity against specific pathogens, enhancKeywords
This publication has 83 references indexed in Scilit:
- Pharmacokinetics of mycophenolate mofetil in patients with end-stage renal failureKidney International, 2000
- Clinical Pharmacokinetics of Mycophenolate MofetilClinical Pharmacokinetics, 1998
- Randomised trial of basiliximab versus placebo for control of acute cellular rejection in renal allograft recipientsThe Lancet, 1997
- Use of In Vitro and In Vivo Data to Estimate the Likelihood of Metabolic Pharmacokinetic InteractionsClinical Pharmacokinetics, 1997
- Pharmacokinetics of Oral Mycophenolate Mofetil in Volunteer Subjects with Varying Degrees of Hepatic Oxidative ImpairmentThe Journal of Clinical Pharmacology, 1996
- Mycophenolate mofetil inhibits lymphocyte binding and the upregulation of adhesion molecules in acute rejection of rat kidney allograftsTransplant Immunology, 1996
- THE USE OF MYCOPHENOLATE MOFETIL (RS-61443) IN HUMAN HEART TRANSPLANT RECIPIENTSTransplantation, 1993
- The IL-2/IL-2 receptor system: A current overviewCell, 1993
- Cloning and sequence analysis of a rapamycin-binding protein-encoding gene (RBP1) from Candida albicansGene, 1992
- Rapamycin (AY-22,989), a new antifungal antibiotic. I. Taxonomy of the producing streptomycete and isolation of the active principle.The Journal of Antibiotics, 1975